
Please try another search
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kit for a –Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs; and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Name | Age | Since | Title |
---|---|---|---|
Mingdong Ran | 49 | 2021 | Independent Director |
Tao Yang | 56 | 2021 | Non-Independent Director |
Manqi Zhao | 50 | 2023 | Chairman of the Supervisory Board |
Ya Chen | 52 | 2012 | Chairman of the Board & GM |
Huang Chen | 49 | 2012 | Deputy GM, Secretary & Director |
Wen Xian | - | 2024 | Accounting Supervisor & Non-Independent Director |
Jia Feng Zhu | 56 | 2015 | Non-Independent Director |
Jie Yan | 60 | 2018 | Non-Independent Director |
Hua Dong Tang | 47 | 2012 | Non-Employee Supervisor |
Jing Du | 42 | 2018 | Supervisor |
Zongfu Mao | - | 2024 | Independent Director |
Haibing Zhou | 55 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review